Research status of radiotherapy combined with EGFR-TKI for brain metastases in patients with EGFR-mutant NSCLC
10.3760/cma.j.cn113030-20210214-00072
- VernacularTitle:EGFR基因突变NSCLC脑转移瘤放疗联合TKI研究现状
- Author:
Xing XIANG
1
;
Wengang YANG
;
Xiaxia CHEN
;
Yichao GENG
;
Zhu MA
;
Shengfa SU
;
Weiwei OUYANG
;
Bing LU
Author Information
1. 贵州医科大学临床医学院肿瘤学教研室 贵州医科大学附属医院/贵州省肿瘤医院胸部肿瘤科，贵阳 550004
- Keywords:
Brain metastasis, non-small-cell lung carcinoma/comprehensive treatment;
Epidermal growth factor receptor;
Tyrosine kinase inhibitor;
Radiotherapy
- From:
Chinese Journal of Radiation Oncology
2021;30(6):637-642
- CountryChina
- Language:Chinese
-
Abstract:
The prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC) is poor. Tyrosine kinase inhibitor (TKI) significantly improves the prognosis of patients with epidermal growth factor receptor (EGFR) sensitive mutation. EGFR sensitive mutations are associated with the incidence of brain metastases in NSCLC and may affect the efficacy of radiotherapy and TKI therapy. Both EGFR-TKI and radiotherapy are effective for EGFR-mutant NSCLC with brain metastases. Whether the combination of EGFR-TKI and radiotherapy may improve the prognosis compared with EGFR-TKI or radiotherapy alone has been studied. Retrospective studies have indicated that upfront radiotherapy, especially upfront stereotaxic radiosurgery combined with EGFR-TKI may be more advantageous in improving the prognosis, but it is still controversial. Therefore, clinical research progresses on the radiotherapy for EGFR-mutant NSCLC patients with brain metastases were reviewed.
